Skip to main content

electroCore, Inc. (ECOR)

NASDAQ: ECOR · IEX Real-Time Price · USD
0.996
-0.001 (-0.06%)
After-hours:Oct 15, 2021 7:43 PM EDT
0.997
-0.003 (-0.34%)
At close: Oct 15, 4:00 PM
Market Cap69.25M
Revenue (ttm)4.48M
Net Income (ttm)-19.09M
Shares Out48.52M
EPS (ttm)-0.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume431,103
Open1.010
Previous Close1.000
Day's Range0.981 - 1.020
52-Week Range0.905 - 3.630
Beta1.17
AnalystsBuy
Price Target3.27 (+228.1%)
Est. Earnings DateNov 4, 2021

About ECOR

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in R...

IndustryHealth Care Equipment & Supplies
IPO DateJun 22, 2018
Employees45
Stock ExchangeNASDAQ
Ticker SymbolECOR
Full Company Profile

Financial Performance

In 2020, electroCore's revenue was $3.50 million, an increase of 46.25% compared to the previous year's $2.39 million. Losses were -$23.51 million, -47.92% less than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for electroCore stock is "Buy." The 12-month stock price forecast is 3.27, which is an increase of 228.12% from the latest price.

Price Target
$3.27
(228.12% upside)
Analyst Consensus: Buy

News

electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents Health Canada expands gammaCore label to include the acute and preventive treatment of migr...

1 day ago - GlobeNewsWire

electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference

ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor...

2 weeks ago - GlobeNewsWire

7 Best Penny Stocks to Buy on the Nasdaq for October

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

2 weeks ago - InvestorPlace

electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimul...

ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-...

2 weeks ago - GlobeNewsWire

electroCore to Participate at Upcoming Investor Conferences

ROCKAWAY, NJ, Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give ...

3 weeks ago - GlobeNewsWire

electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy...

ROCKAWAY, NJ, Sept. 15, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office ...

1 month ago - GlobeNewsWire

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal ...

ROCKAWAY, NJ, Sept. 14, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Sec...

1 month ago - GlobeNewsWire

electroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference

ROCKAWAY, NJ, Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a...

1 month ago - GlobeNewsWire

electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.

ROCKAWAY, NJ, Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LL...

1 month ago - GlobeNewsWire

electroCore Announces Second Quarter 2021 Financial Results

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET Second quarte...

2 months ago - GlobeNewsWire

ElectroCore Analyst: Nerve Stimulation Market Opportunity Is Large

A combination of a large total addressable market, regulatory clearance, strong partnerships and effective product has Ladenburg Thalmann analysts bullish on electroCore, Inc. (NASDAQ:ECOR). The electro...

2 months ago - Benzinga

ElectroCore Stock Is Trading Higher As Ladenburg Initiates Coverage With $3 Price Target, Buy Rating

Ladenburg Thalmann has initiated coverage of ElectroCore Inc (NASDAQ: ECOR) with a Buy rating and $3 price target, implying an upside of around 190%. The Company's gammaCore Sapphire device is currently...

2 months ago - Benzinga

electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

ROCKAWAY, NJ, July 27, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (...

2 months ago - GlobeNewsWire

electroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Ne...

ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical...

2 months ago - GlobeNewsWire

electroCore to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

ROCKAWAY, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overv...

3 months ago - GlobeNewsWire

ElectroCore Stock Dives On $18M Equity Raise Issued At Deep Discount Of 32%

ElectroCore Inc (NASDAQ: ECOR) has priced underwritten public offering of 18 million shares at $1 per share, representing a discount of 32% from the last close price of $1.48 on Tuesday. The gross proce...

3 months ago - Benzinga

electroCore Announces Pricing of $18.0 Million Public Offering of Common Stock

ROCKAWAY, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the pricing of an underwritten publi...

3 months ago - GlobeNewsWire

electroCore Announces Proposed Public Offering of Common Stock

ROCKAWAY, NJ, June 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell sha...

3 months ago - GlobeNewsWire

electroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive ...

ROCKAWAY, NJ, June 24, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10,...

3 months ago - GlobeNewsWire

electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits

ROCKAWAY, NJ, June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its...

4 months ago - GlobeNewsWire

electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcome...

ROCKAWAY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled ...

4 months ago - GlobeNewsWire

electroCore to Present at Investor Conferences in June

ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several invest...

4 months ago - GlobeNewsWire

electroCore, Inc. Celebrates Veterans and Active Members of the Military During National Military Appreciation Month

ROCKAWAY, N.J.--(BUSINESS WIRE)--National Military Appreciation Month commemorates and expresses gratitude for the sacrifices current and former members of the U.S. armed forces have made for our countr...

4 months ago - Business Wire

electroCore Supports Results of Lancet Paper Highlighting the Benefits of Vagus Nerve Stimulation for Stroke Patients

ROCKAWAY, N.J.--(BUSINESS WIRE)--electroCore, Inc., a commercial-stage bioelectronic medicine company, commends the results of the VNS-REHAB study published in the April 24th edition of The Lancet which...

4 months ago - Business Wire

electroCore Announces First Quarter 2021 Financial Results

Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially

5 months ago - GlobeNewsWire